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Abstract 
Magnetic resonance imaging (MRI) now provides valuable diagnostic and prognostic information for the 
management of multiple sclerosis (MS) but the diagnosis still largely rests on the clinical features of central 
nervous system (CNS) lesions disseminated in time and place. Recent histological and MRI studies indicate 
that extensive axonal damage can occur in MS, even early in the disease course, and is likely to be an 
important cause of accumulating disability. Several immunomodulating agents have now been shown to 
have beneficial effects in MS. High dose intravenous or high dose oral methylprednisolone therapy 
accelerates recovery from attacks of relapsing-remitting MS, but at present there is no convincing evidence 
that standard dose (intermediate dose) oral corticosteroid therapy is beneficial for such attacks. Interferon 
beta, copolymer 1 (glatiramer acetate) and i.v. immunoglobulin therapy each significantly reduce the 
frequency of attacks of relapsing-remitting MS. Interferon beta also inhibits the progression of disability in 
relapsing-remitting MS and secondary progressive MS, but its effect on primary progressive MS is 
unknown. Oral low dose methotrexate therapy slows the progression of disability in secondary progressive 
MS and possibly in primary progressive MS, but it is likely that the currently used dosage (7.5 mg weekly) 
is suboptimal. Further research is needed to determine the optimal doses and combinations of the above 
therapies in MS and to develop better therapies, particularly for primary progressive MS.  
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Introduction  
 
Multiple sclerosis (MS) is a chronic, inflammatory demyelinating disease of the central nervous 
system (CNS). It is a common cause of neurological disability, particularly in young adults. There 
is increasing evidence that MS is an autoimmune disease. 1,2 This review will focus on recent 
progress in the diagnosis, prognosis and treatment of MS. The sections on treatment will deal 
with immunomodulatory therapy aimed at modifying the disease course rather than with 
symptomatic therapy. The review will also discuss recent insights into the pathophysiology of MS 
that are relevant to patient management. 
 
Diagnosis and Prognosis  
 
The diagnosis of MS requires the demonstration of CNS lesions disseminated in time and place. 3 
Thus it is not possible to make a definitive diagnosis of MS at the time of presentation of the first 
neurological episode, even if magnetic resonance imaging (MRI) of the brain reveals multiple 
lesions typical of MS. Nevertheless an MRI brain scan at the time of presentation of a clinically 
isolated syndrome of the optic nerve, brain stem or spinal cord can provide valuable prognostic 
information. O'Riordan et al. 4 have recently reported the results of a 10 year follow-up study on 
81 patients who had T2-weighted brain MRI at the time of presentation of such clinically isolated 
syndromes. Of those patients with an abnormal MRI, 83% had progressed to clinically definite 
MS whereas, of those with a normal MRI, only 11% had progressed to clinically definite MS. 
There was also a significant relationship between the number of brain MRI lesions at presentation 
and both disability and the type of disease at follow-up. Patients who followed a benign course of 
MS had few (median=3) MRI lesions at presentation, whereas those who developed secondary 
progressive MS with a high level of disability at 10 years' follow-up had many (median=18) 
lesions at presentation. Barkhof et al. 5 have evaluated the utility of individual brain MRI criteria 
at the time of first presentation in predicting the subsequent development of clinically definite 
MS. They found that gadolinium enhancement was the most predictive MRI parameter and that a 
combination of gadolinium enhancement (one or more lesions), juxtacortical (contiguous with the 
cerebral cortex) lesions (one or more), infratentorial lesions (one or more) and periventricular 
lesions (three or more) best predicted the development of clinically definite MS, with a sensitivity 
of 82%, a specificity of 78% and an accuracy of 80%. 
 MS can be subdivided into a number of different clinical subtypes on the basis of the 
clinical course but, in the past, confusion has sometimes arisen from a lack of standardized 
terminology. As a result of an international survey, Lublin and Reingold 6 have proposed 
standardized definitions for the most common clinical subtypes of MS (Table 1).  
 
Table 1  Consensus definitions of the clinical subtypes of multiple sclerosis* 
Relapsing-remitting MS 
Clearly defined disease relapses with full recovery or with sequelae and residual deficit upon recovery; 
periods between disease relapses characterized by a lack of disease progression. 
Secondary progressive MS 
Initial relapsing-remitting course followed by progression with or without occasional relapses, minor 
remissions and plateau. 
Primary progressive MS 
Disease progression from onset with occasional plateaux and temporary minor improvements allowed. 
Progressive-relapsing MS 
Progressive disease from onset, with clear acute relapses, with or without full recovery; periods between 
relapses characterized by continuing progression. 
Benign MS 
Disease in which the patient remains fully functional in all neurologic systems 15 years after disease onset. 
 
*From Lublin and Reingold 6 
 
The diagnosis of relapsing-remitting MS and of secondary progressive MS is relatively 
straightforward; however, the definitive diagnosis of primary progressive MS using the criteria of 
Poser et al. 3 and Lublin and Reingold 6 remains difficult. 7,8 A diagnosis of laboratory supported 
definite primary progressive MS can be made when there is evidence of intrathecal 
immunoglobulin synthesis, a progressive neurological course and evidence of at least two 
separate lesions developing at different times. In the absence of evidence of intrathecal 
immunoglobulin synthesis, some would argue that a diagnosis of clinically definite primary 
progressive MS can be made if there is disease progression and symptoms and neurological signs 
of two separate lesions commencing at least one month apart, with the possibility of MRI or 
electrophysiological symptoms, of a second lesion. However, others would argue that using the 
criteria of Poser et el. 3 it is not possible to make a diagnosis of clinically definite primary 
progressive MS because the criteria require the presence of at least two discrete attacks, which by 
definition do not occur in primary progressive MS. 8 The diagnostic difficulty in primary 
progressive MS is compounded by the fact that brain MRI may be normal in this form of MS 
when there are multiple visible lesions in the spinal cord, 9 and by the fact that MRI brain lesions 
not due to MS are more frequent in the older age group in which primary progressive MS tends to 
occur. 7 At present it is often difficult to exclude confidently all other diseases that may mimic 
primary progressive MS. There is, therefore, a need to define the diagnostic criteria of primary 
progressive MS more precisely; this is particularly important for therapeutic trials, as currently 
there is a paucity of reliable information concerning the treatment of primary progressive MS. It 
is possible that, with better diagnostic criteria, the current estimate that 10% of MS patients have 
a primary progressive course 7 will prove to be an underestimate. 
 
Pathophysiology  
 
Axonal damage  
Primary demyelination is the pathological hallmark of MS and is considered to be a major cause 
of the neurological symptoms and signs, but it has been known since the time of Charcot that 
axonal damage also occurs in MS. 10 Recent studies indicate that axonal damage is more common 
in MS and contributes to clinical disability to a greater extent than previously thought. In a 
histological study Trapp et el. 11 have shown that axonal transection is a consistent feature of the 
lesions of MS. They found that axonal transection was abundant in active and chronic active 
lesions from patients with durations of clinical disease ranging from 2 weeks to 27 years. The 
frequency of transected axons was related to the degree of inflammation within the lesion, 
suggesting that the axonal transection was caused by the acute inflammatory process rather than 
being a consequence of chronic demyelination. Ferguson et al. 12 have also shown that axonal 
damage, as indicated by the accumulation of amyloid precursor protein, is closely associated with 
inflammation in MS lesions. Recent studies employing MRI and magnetic resonance 
spectroscopy (MRS) indicate that axonal loss is an important cause of persistent neurological 
disability in MS. Using MRI to measure the cross-sectional area of the spinal cord at the C2 level, 
Losseff et al. 13 found a strong graded correlation between spinal cord atrophy (probably mainly 
due to axonal loss) and disability measured on the Kurtzke Expanded Disability Status Scale 
(EDSS). Similarly, the presence of cerebellar ataxia in MS is correlated with the presence of 
cerebellar atrophy on MRI and with a reduction in the concentration of the neuronal marker, N-
acetylaspartate, in the cerebellar white matter on MRS. 14 Furthermore, a serial MRI study has 
revealed that progressive cerebral atrophy correlates with sustained deterioration in the EDSS 
score. 15 There is also a significant correlation between the progression of disability in secondary 
progressive MS and the accumulation of hypointense T1 lesions (black holes), 16 which represent 
regions of substantial axonal loss. 17 
It has been hypothesized that the clinical course of MS may vary according to which 
antigens in the CNS are being targeted by the immune system. 18 Targeting of myelin antigens 
may lead to a relapsing-remitting course with clinical recovery due to remyelination; targeting of 
axonal antigens may lead to a progressive course from onset because axonal regeneration is 
limited in the CNS. The transition from relapsing-remitting MS to secondary progressive MS may 
involve the spreading of the immune response to axonal antigens or increased bystander damage 
to axons near to myelin directed immune attack. TM The occurrence of axonal damage in MS has 
implications for therapy. Therapy that inhibits the immune attack on the CNS would not be 
expected to restore neurological function if the axon is the major target of the immune attack 
whereas, if myelin is the major target, restoration of function may occur as a result of 
remyelination unhindered by repeated immune attacks. The occurrence of axonal damage in at 
least some cases of early MS emphasizes the need to develop treatments that prevent further 
immune mediated axonal damage and accumulating disability. 
 
Mechanism of fatigue  
Fatigue is a common severe disabling symptom of MS. The mechanism of fatigue in MS has been 
poorly understood, but two recent studies have shed light on its pathophysiology. In an 
electrophysiological study of the decline in strength during a sustained maximal muscular 
contraction, Sheean et al. concluded that the fatigue in MS patients originates in the CNS rather 
than in muscle) 9 They found that the fatigue in MS patients is unlikely to result from frequency 
dependent conduction block in primary central motor pathways and suggested that it is due to an 
impaired drive to the primary motor cortex. This suggestion is supported by the study of Roelcke 
et el. 20 who used positron emission tomography and 18F-fluorodeoxyglucose to measure cerebral 
glucose metabolism. They found that severe fatigue in MS is associated with a reduction in 
glucose metabolism in the prefrontal cortex, adjacent white matter and basal ganglia, and 
concluded that fatigue may result from demyelination of the frontal white matter. This is 
consistent with the previously reported correlation between fatigue and impaired cognition in the 
early stages of MS. 21 The possibility that fatigue may indicate primary demyelination or axonal 
damage in the cerebrum has implications for the treatment of MS. If this is confirmed by further 
research, severe fatigue may itself become an indication for the treatment of MS in order to 
minimize further CNS damage. 
 
Corticosteroid therapy  
 
Intravenous high dose methylprednisolone therapy, 500 mg daily for 5 days, accelerates recovery 
from acute attacks of relapsing-remitting MS compared to placebo; 22 it also results in 
improvement in patients with progressive MS although the benefit is considerably less than for 
acute attacks. Durelli et el. 23 have also shown that i.v. high dose methylprednisolone therapy 
accelerates recovery from attacks of relapsing-remitting MS, but they used a more complicated 
regimen of 15 mg per kg per day for 3 days followed by i.v. infusions of tapering doses for 
another 12 days and then oral prednisone for 120 days. Intravenous high dose methylprednisolone 
therapy, 1 g daily for 3 days, followed by oral prednisone therapy (1 mg per kg of body weight 
per day for 11 days) also accelerates recovery from acute optic neuritis compared to placebo. 24 
The optimal dose of i.v. methylprednisolone therapy is unclear. Oliveri et al. 25 compared the 
efficacy of 2.0 g daily for 5 days with 0.5 g daily for 5 days in the treatment of MS relapses. They 
found that, although the two doses of i.v. methylprednisolone were equally efficacious in 
improving disability, the higher dose was significantly more effective in reducing the number of 
gadolinium enhanced MRI brain lesions at 30 and 60 days after the beginning of treatment; this 
greater efficacy was mainly due to a greater inhibition of new lesion formation. 
 In contrast to i.v. high dose methylprednisolone, oral prednisone alone in standard 
(intermediate) doses (1 mg per kg per day for 14 days) has no beneficial effect on acute optic 
neuritis compared to placebo and may increase the risk of new episodes of optic neuritis. 24 One 
study has reported that oral intermediate dose methylprednisolone therapy alone for 21 days (48 
mg daily for 7 days, followed by 24 mg daily for 7 days and then 12 mg daily for 7 days) is 
equally as effective as i.v. high dose methylprednisolone therapy (1 g daily for 3 days) for the 
treatment of acute relapses of MS. 26 The authors recommended that oral intermediate dose 
corticosteroid therapy be used instead of i.v. high dose methylprednisolone because the former is 
more convenient to use and more cost effective, as it does not require hospitalization. However, 
in that study, both oral therapy and i.v. therapy had marginal beneficial effects (0.5 EDSS points) 
compared to the previously reported effect (2.0 EDSS points) of i.v. high dose 
methylprednisolone. 22 The poor efficacy of i.v. methylprednisolone therapy may have been 
related to the high proportion of severely disabled patients (EDSS >6.0) in the study, 26 which 
raises the possibility that a considerable proportion of these patients had permanent neurological 
deficits due to axonal loss and would not have been expected to respond to corticosteroid therapy. 
Better evidence for a beneficial effect of oral intermediate dose corticosteroid therapy needs to be 
provided before it can be advocated for the treatment of MS relapses. 
 Oral high dose methylprednisolone therapy (500 mg once daily for 5 days followed by a 
tapering dose over the next 10 days) has recently been shown to significantly accelerate recovery 
from attacks of relapsing-remitting MS, compared to placebo, 27 The treatment was generally well 
tolerated, although 38% of patients receiving oral high dose methylprednisolone experienced 
gastrointestinal symptoms. An earlier study found that oral high dose methylprednisolone therapy 
(500 mg daily for 5 days) was as effective as the same dose of i.v. high dose methylprednisolone 
therapy in the treatment of acute relapses of MS. 28 It is unclear whether this regimen of oral high 
dose methylprednisolone can be safely used in routine clinical practice. A problem with the use of 
oral corticosteroid therapy is that, because of its ease of use, it tends to be prescribed frequently 
and for prolonged periods leading to chronic corticosteroid use, sideeffects and dependence. 29 In 
contrast, i.v. administration alerts both patients and physicians to the fact that the indication for its 
use has to be strong. Intravenous high dose methylprednisolone therapy is recommended for the 
treatment of moderate to severe attacks of MS not improving spontaneously. At the present time, 
mild attacks are probably best left untreated. 
 
Interferon beta  
 
The S.C. administration of 8 million international units of interferon beta-1b every second day 
has been shown to reduce the frequency of relapses of relapsing-remitting MS by one-third in a 
multicentre, randomized, double-blind, placebo-controlled trial. 30 This treatment also reduces the 
severity of relapses 30 and reduces the occurrence of new MRI brain lesions and the MRI detected 
burden of disease (accumulation of abnormal white matter on T2-weighted brain MRI). 31 The 
entry criteria for this study were a diagnosis of clinically definite or laboratory supported definite 
MS of the relapsing-remitting type, an EDSS score of 0-5.5 (an EDSS score of 5.5 is equivalent 
to ambulation for 100 m, but not farther, without aid or rest), and at least two exacerbations in the 
previous 2 years. The beneficial effect of this therapy on the frequency of relapses and on the 
accumulation of MRI brain lesions was sustained for at least 5 years after commencement of 
therapy. 32 A lower dose (1.6 million units every second day) of interferon beta-1b also reduced 
the relapse rate and the accumulation of MRI lesions compared to placebo, but the effects were 
less than those of the dose of 8 million units. This study did not demonstrate a significant 
beneficial effect of interferon beta-1b therapy on the progression of disability; however, it was 
not originally designed to detect such an effect. Interferon beta-1b therapy also significantly 
reduces the number of gadolinium enhanced MRI lesions in patients with relapsing-remitting MS. 
33 Gadolinium enhancement indicates a breakdown of the blood-brain barrier and correlates with 
a marked perivascular accumulation of inflammatory cells; 34 it precedes other MRI abnormalities 
and clinical evidence of the new lesion. 35 
 In general, treatment with interferon beta-1b is well tolerated. The most common adverse 
effects are flu-like symptoms and injection site reactions. 36 The flu-like symptoms include fever, 
chills, myalgia, headache and malaise. The increase in body temperature may transiently 
aggravate the symptoms and signs of MS by reversibly increasing conduction block in previously 
demyelinated fibres. These flu-like symptoms tend to resolve after the first few months of therapy 
and can be controlled by the use of paracetamol or ibuprofen just prior to injection and 4 h later. 
The most common injection site reaction is redness which is sometimes painful; this tends to 
resolve after the first month of therapy. Bruising (with pain) and cutaneous or S.C. infections 
usually indicate a poor injection technique. Subcutaneous atrophy may occur and rarely painful 
necrotic lesions can occur at the injection sites. Education of the patient, for example by a trained 
nurse, regarding the injection technique is very important in reducing injection site reactions and 
maximizing compliance. The injections are usually given in the buttocks, anterior thighs or lower 
abdomen and are facilitated by the use of an automatic self-injecting device. It is also 
recommended that the initial seven doses be halved to 4 million units as this appears to lower the 
incidence of flu-like symptoms and injection site reactions. Interferon beta-1b may also cause 
anaemia, leukopaenia, thrombocytopaenia or elevation of hepatic enzyme levels. It is unclear 
whether it aggravates depression and increases the frequency of suicide attempts, but active 
severe depression should be regarded as a contraindication to the use of interferon beta-1b. 36 
 Interferon beta-1b is also contraindicated in pregnant women, in those who are actively 
attempting to become pregnant and in those who are breastfeeding. 
 Neutralizing antibodies to interferon beta have been reported to occur in 35% of patients 
treated with interferon beta-1b and to be associated with a reduction in the beneficial effect of 
therapy on relapse rate and MRI lesions. 37 It is also possible that binding, nonneutralizing 
antibodies may interfere with the bioactivity of interferon beta. 38 Further research is needed to 
determine the clinical significance of antibodies to interferon beta and to detetmine which is the 
best assay to measure these antibodies. Another form of interferon beta, namely interferon beta-
la, has also been shown to have a beneficial effect on relapsing-remitting MS. 39 Interferon beta-la 
is a natural sequence, glycosylated, recombinant Chinese hamster ovary product whereas 
interferon beta-1b is a serine substituted, non-glycosylated recombinant protein produced by 
Escherichia coli. The intramuscular injection of 6 million units (30 µg) of interferon beta-1a 
(Avonex, Biogen Inc.) weekly has been shown to reduce the frequency of relapses of relapsing-
remitting MS by one-third and to reduce the number and volume of gadolinium enhanced MRI 
brain lesions. 39 Importantly it significantly delayed the time to sustained progression of disability. 
Neutralizing antibodies also develop in patients treated with interferon beta-1a. 40 The frequency 
(6%) of neutralizing antibodies after 18 months of interferon beta-la therapy was found to be 
considerably lower than after a similar period of treatment with interferon beta-1b, but it is 
unclear whether this was related to differences in the dose, frequency of administration or route of 
administration, chemical differences between the two forms of interferon beta, or other factors. It 
should be noted that those treated with interferon beta-1b were studied after they decided to 
discontinue treatment, whereas the group treated with interferon beta-la were beginning interferon 
beta therapy for the first time. This raises the possibility that the presence of neutralizing 
antibodies in the group discontinuing interferon beta-1b may have influenced the decision to stop 
the drug, thus questioning the validity of the comparison. 41 
 A recent study has examined the effects of two different doses of interferon beta-la 
(Rebif, Ares-Serono) in relapsing-remitting MS. 42 Interferon beta-la was given subcutaneously 
because it has been shown that the bioavailability Of interferon beta-la is equivalent after the s.c. 
or intramuscular administration of Rebif and intramuscular administration of Avonex 43 and 
because the s.c. route is more convenient for the patient than the intramuscular route. In this large 
study 42 560 patients with EDSS scores of 0-5.0 and at least two relapses in the previous 2 years 
were randomized to receive s.c. recombinant interferon beta-1a (Rebif) 22 µg (6 million units), 
interferon beta-1a 44 µg, or placebo, three times weekly for 2 years. Both doses of interferon 
beta-1a significantly reduced the number of relapses (22 µg, 27% reduction; 44 µg, 33 % 
reduction) compared to placebo. Interferon beta-1a treatment significantly delayed progression of 
disability (first quartile of time to progression: placebo, 11.9 months; 22 µg, 18.5 months; 44 µg, 
21.3 months) and decreased accumulated disability during the study. The number of active MRI 
lesions and the MRI detected burden of disease were reduced in both treatment groups. The 
reduction in active MRI lesions was significantly greater in patients receiving the higher dose 
than in those receiving the lower dose. Interestingly, the 44 µg dose of interferon beta-1a was 
associated with a lower rate of neutralizing antibodies at 2 years than the 22 µg dose (12.5% vs 
23.8%). Furthermore, in the group of patients with a baseline EDSS>3.5, who are likely in the 
short term to develop secondary progressive MS, the 44 µg dose delayed progression of disability 
significantly better than either the 22 µg dose or placebo. Both doses of interferon beta-la were 
generally well tolerated and there was no increased incidence of depression or suicide attempts in 
either treatment group compared to placebo. 
 All of the above studies have been performed on patients with relapsing-remitting MS. A 
recent European multi-centre, placebo-controlled trial has shown that interferon beta-1b (8 
million international units subcutaneously every second day) significantly slows the progression 
of disability in patients with secondary progressive MS. 44 This beneficial effect was observed in 
both those with and without superimposed relapses and was consistent throughout the entire 
EDSS range studied (3.0-6.5). It was estimated that interferon beta-1b delayed the progression of 
disability by 9-12 months in a study period of 2-3 years. Treatment with interferon beta-1b also 
significantly reduced the mean MRI T2 lesion volume and the number of newly active MRI 
lesions. The effect of interferon beta in primary progressive MS is unknown. The mechanism of 
action of interferon beta in MS is unclear but one possibility is that it may prevent activated T 
lymphocytes from trafficking into the CNS. Interferon beta therapy leads to an increase in the 
serum level of soluble vascular cell adhesion molecule-1 (VCAM-1) which correlates with the 
decrease in the number of gadolinium enhanced MRI lesions. 45 Binding of soluble VCAM-1 to 
its lymphocyte ligand, very late antigen-4 (VLA-4), may be responsible for the observed decrease 
in the expression of VLA-4 by peripheral blood lymphocytes in MS patients treated with 
interferon beta. 46 As the interaction between VLA-4 and VCAM-1 may play a role in the entry of 
lymphocytes into the CNS, it has been suggested that the down-regulation of lymphocyte 
expression of VLA-4 may contribute to the beneficial effect of interferon beta in MS .46 Another 
possible mechanism for the beneficial effect of interferon beta is the induction of the 
immunosuppressive cytokine, interleukin-10. Rudick et al,47 have shown that interferon beta 
increases interleukin-10 levels in the serum and cerebrospinal fluid (CSF) of patients with 
relapsing-remitting MS; they also found that increased CSF levels of interleukin-10 correlated 
with a favourable therapeutic response. 
 
Copolymer 1 (Glatiramer Acetate)  
 
Copolymer 1 (glatiramer acetate) is a mixture of random synthetic polypeptides composed of L-
alanine, L-glutamic acid, L-lysine and L-tyrosine in a molar ratio of 6.0:1.9:4.7:1.0. It was 
designed to simulate myelin basic protein, a putative target antigen in MS. After it was found to 
inhibit experimental autoimmune encephalomyelitis (EAE), a pilot study suggested that it had a 
beneficial effect in relapsing-remitting MS. 48 An extensive multi-centre, double-blind, placebo-
controlled trial has now shown that the daily S.C. injection of 20 mg of copolymer 1 for 2 years 
significantly reduces the relapse rate of relapsing-remitting MS by 29% compared to placebo. 49 
There was also some evidence that copolymer 1 had a beneficial effect on the progression of 
disability. The treatment was well tolerated. The most common adverse effect was an injection 
site reaction consisting of erythema and induration which occurred in 90% of patients receiving 
copolymer 1. The other adverse effect was a transient self limited systemic reaction consisting of 
flushing and chest tightness, sometimes with dyspnoea, palpitations or anxiety; this occurred after 
one or more injections in 15% of patients. The mechanism responsible for the beneficial effect of 
copolymer 1 in MS is unclear. Copolymer 1 may have a place in the treatment of those patients 
with relapsing-remitting MS who become resistant to interferon beta therapy because of the 
development of antibodies against interferon beta. However, further studies are required to 
determine the effects of long-term treatment with copolymer 1. 
 
I.V. Immunoglobulin Therapy  
 
Intravenous immunoglobulin therapy is effective in the treatment of a number of autoimmune 
diseases, although the mechanism of action is unclear. A randomized, placebo-controlled trial has 
shown that the monthly i.v. infusion of immunoglobulin (0.15-0.20 g per kg) for 2 years 
significantly reduced the relapse rate of relapsing-remitting MS by 59% and had a significant 
beneficial effect on the progression of disability, compared to placebo9 The treatment was well 
tolerated. A similar beneficial effect of i.v. immunoglobulin on relapse rate was found in a 
smaller study in which patients received a loading dose of 0.4 g per kg per day for 5 consecutive 
days, followed by single booster doses (0.4 g per kg) once every 2 months for 2 years. 51 A very 
high dose of i.v. immunoglobulin (1 g per/2g daily for 2 consecutive days every month for 6 
months) significantly reduced the number of gadolinium enhanced MRI brain lesions compared 
to placebo; 52 however/this is clearly above the maximum tolerated dose, as it resulted in a high 
frequency of severe eczema which usually commenced in the palms of the hands and developed 
2-4 days after the first or later courses of i.v. immunoglobulin. On present evidence, i.v. 
immunoglobulin therapy may be as effective as interferon beta in the treatment of relapsing-
remitting MS, 50 but further studies are needed to determine the effects of its long-term use in MS. 
 
Immunosuppressive therapy  
 
Given the increasing evidence that MS is an autoimmune disease and the fact that other 
autoimmune diseases respond to immunosuppressive therapy, it would be anticipated that such 
therapy would be beneficial in MS. Most of the clinical trials of immunosuppression in MS have 
been performed on patients with progressive MS rather than relapsing-remitting MS. As much of 
the persistent disability in progressive MS is probably due to axonal damage, it is likely that the 
main benefit able to be obtained from effective immunosuppression is the prevention of an 
increase in disability rather than reversal of pre-existing disability. This may account for the 
modest and disappointing effects of immunosuppressive therapy in progressive MS in the studies 
performed to date. 
 
Azathioprine  
A meta-analysis of the results of published blind, randomized, controlled trials of azathioprine 
therapy (2-3 mg per kg per day) in relapsing-remitting MS and progressive MS showed that this 
therapy reduces the frequency of relapses and possibly slows the progression of disability. 53 It is 
doubtful whether the slight beneficial effect of azathioprine outweighs its side-effects. 
 
Cyclosporin A  
Cyclosporin A therapy has a modest beneficial effect on the progression of disability in 
progressive MS, 54 but the high incidence of severe adverse effects, particularly renal impairment 
and hypertension, makes it an unsuitable therapeutic agent for MS. As low dose cyclosporin A 
therapy converts acute EAE into chronic relapsing EAE, the possibility that cyclosporin A may 
aggravate MS in some patients needs to be considered. 55 
 
Methotrexate  
Oral low dose methotrexate therapy is an effective and relatively safe treatment for the common 
chronic autoimmune diseases, rheumatoid arthritis and psoriasis. A randomized, double-blind, 
placebo-controlled trial has shown that oral methotrexate 7.5 mg weekly for 2 years significantly 
reduces the rate of progression of disability in progressive MS.56 The beneficial effect was 
evident in tests of upper limb function but not in the ambulation index or the EDSS score which is 
mainly determined by walking ability. The clinical benefit was observed in patients with 
secondary progressive MS, but too few patients with primary progressive MS were included to 
assess efficacy in the latter group. The methotrexate therapy also had a beneficial effect on the 
total T2-weighted lesion area in MRI brain scans. 57 It is highly likely that the 7.5 mg dose is 
inadequate, as considerably higher weekly doses (12.5 mg) are regularly used in the management 
of patients with rheumatoid arthritis. An insufficient dose may account for the failure of the 
therapy to slow deterioration of ambulation. The extent of axonal loss in CNS motor and sensory 
pathways is likely to be greater for the lower limbs than for the upper limbs, with the result that 
measurements of lower limb function may be less sensitive to immunosuppression than 
measurements of upper limb function. Currently, methotrexate appears to be the best 
immunosuppressive agent for slowing deterioration in progressive MS. Further clinical trials are 
needed to determine whether higher doses of oral methotrexate are more effective than the 7.5 mg 
weekly dose and to determine the relative benefits of methotrexate therapy and interferon beta 
therapy in progressive MS. Oral low dose methotrexate is generally well tolerated but requires 
regular monitoring of the full blood count and liver function. It is important to name the day (for 
example, Monday) of the week on which the methotrexate is to be taken, in order to avoid the 
possibility of the patient taking the dose daily instead of weekly. If a dose exceeding 7.5 mg is 
used, the patient should take folic acid 5 mg, 3 days after the methotrexate dose. 
 
Cyclophosphamide  
Cyclophosphamide is too toxic to be used for the treatment of MS, with the possible exception of 
rapidly progressive MS not responding to methotrexate. 58 
 
Conclusion  
 
In conclusion, several immunomodulating agents have now been shown to have beneficial effects 
in MS. Further research is needed to determine the optimal doses and combinations of these 
therapies and to develop better therapies, particularly for primary progressive MS. 
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